nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

03.08.2017 | Image of the Month

Visualization of HER2-specific breast cancer intratumoral heterogeneity using ⁶⁴Cu-DOTA-trastuzumab PET

verfasst von: Shinsuke Sasada, Hiroaki Kurihara, Takayuki Kinoshita, Masayuki Yoshida, Natsuki Honda, Tatsunori Shimoi, Akihiko Shimomura, Kan Yonemori, Chikako Shimizu, Akinobu Hamada, Yousuke Kanayama, Yasuyoshi Watanabe, Yasuhiro Fujiwara, Kenji Tamura

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Excerpt

Evaluation of human epidermal growth factor receptor 2 (HER2) expression in tumor tissues using immunohistochemistry (IHC) or in situ hybridization (ISH) has revealed heterogeneity in invasive breast cancers [1]. Previously, we reported that ⁶⁴Cu-DOTA-trastuzumab PET (HER2 PET) imaging can noninvasively identify HER2-positive breast cancers [2‐4]. …

Pekar G, Gere M, Tarjan M, Hellberg D, Tot T. Molecular phenotype of the foci in multifocal invasive breast carcinomas: intertumoral heterogeneity is related to shorter survival and may influence the choice of therapy. Cancer. 2014;120:26–34. doi:10.1002/cncr.28375.CrossRefPubMed

Tamura K, Kurihara H, Yonemori K, Tsuda H, Suzuki J, Kono Y, et al. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med. 2013;54:1869–75. doi:10.2967/jnumed.112.118612.CrossRefPubMed

Kurihara H, Hamada A, Yoshida M, Shimma S, Hashimoto J, Yonemori K, et al. (64)cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. EJNMMI Res. 2015;5:8. doi:10.1186/s13550-015-0082-6.CrossRefPubMedPubMedCentral

Sasada S, Kurihara H, Kinoshita T, Yoshida M, Honda N, Shimoi T, et al. (2017) 64Cu-DOTA-trastuzumab PET imaging for HER2-specific primary lesions of breast cancer. Ann Oncol. doi:10.1093/annonc/mdx227.PubMed

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4013. doi:10.1200/jco.2013.50.9984.CrossRefPubMed

Titel: Visualization of HER2-specific breast cancer intratumoral heterogeneity using 64Cu-DOTA-trastuzumab PET
verfasst von: Shinsuke Sasada
Hiroaki Kurihara
Takayuki Kinoshita
Masayuki Yoshida
Natsuki Honda
Tatsunori Shimoi
Akihiko Shimomura
Kan Yonemori
Chikako Shimizu
Akinobu Hamada
Yousuke Kanayama
Yasuyoshi Watanabe
Yasuhiro Fujiwara
Kenji Tamura
Publikationsdatum: 03.08.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 12/2017
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-017-3781-6

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Visualization of HER2-specific breast cancer intratumoral heterogeneity using ⁶⁴Cu-DOTA-trastuzumab PET

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2017

Grading and outcome prediction of pediatric diffuse astrocytic tumors with diffusion and arterial spin labeling perfusion MRI in comparison with 18F–DOPA PET

Bone SPECT/CT in the postoperative spine: a focus on spinal fusion

The role of F-18 FDG PET/CT in evaluating the impact of HIV infection on tumor burden and therapy outcome in patients with Hodgkin lymphoma

Measurement uncertainty and clinical impact of target-to-background ratios derived by interim FDG-PET/CT in Hodgkin lymphoma: reply to Laffon and Martan

Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resection

Elevated tumor-to-liver uptake ratio (TLR) from 18F–FDG-PET/CT predicts poor prognosis in stage IIA colorectal cancer following curative resection